- Home
- MTNB vs SILO Comparison
MTNB vs SILO Comparison
Compare MTNB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- SILO
- Stock Information
- Founded
- MTNB 2013
- SILO 2010
- Country
- MTNB United States
- SILO United States
- Employees
- MTNB N/A
- SILO N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- MTNB Health Care
- SILO Consumer Discretionary
- Exchange
- MTNB Nasdaq
- SILO Nasdaq
- Market Cap
- MTNB 3.6M
- SILO 3.1M
- IPO Year
- MTNB N/A
- SILO N/A
- Fundamental
- Price
- MTNB $0.83
- SILO $0.48
- Analyst Decision
- MTNB Hold
- SILO
- Analyst Count
- MTNB 1
- SILO 0
- Target Price
- MTNB N/A
- SILO N/A
- AVG Volume (30 Days)
- MTNB 354.4K
- SILO 643.9K
- Earning Date
- MTNB 05-15-2025
- SILO 05-09-2025
- Dividend Yield
- MTNB N/A
- SILO N/A
- EPS Growth
- MTNB N/A
- SILO N/A
- EPS
- MTNB N/A
- SILO N/A
- Revenue
- MTNB N/A
- SILO $72,102.00
- Revenue This Year
- MTNB N/A
- SILO $1.86
- Revenue Next Year
- MTNB N/A
- SILO N/A
- P/E Ratio
- MTNB N/A
- SILO N/A
- Revenue Growth
- MTNB N/A
- SILO N/A
- 52 Week Low
- MTNB $0.47
- SILO $0.41
- 52 Week High
- MTNB $9.60
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- MTNB 60.02
- SILO 36.01
- Support Level
- MTNB $0.77
- SILO $0.43
- Resistance Level
- MTNB $1.17
- SILO $0.50
- Average True Range (ATR)
- MTNB 0.12
- SILO 0.04
- MACD
- MTNB -0.00
- SILO 0.01
- Stochastic Oscillator
- MTNB 30.72
- SILO 46.27
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.